It will be so interesting to learn more about the influences of the microbiome on responses to immunotherapy and even other therapies that we are using.

    I haven’t had this exact scenario but have seen a lot of esophagitis in my immunotherapy patients. Generally have treated as described above with use of corticosteroids in addition to typical supportive care therapies utilized in this setting (PPI, H2 blocker, coating agents at maximum doses to start and then tapering along with steroids as symptoms improve).

    Latest Activity